

Date: 13th September, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
BSE Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its API - I & API - II Facility located at Panelav.

Ref.: Our earlier intimation dated 31st May, 2025 - USFDA inspection at Alembic Pharmaceuticals Limited's API - I & API - II Facility located at Panelav.

We would like to inform the exchange that the Company has received Establishment Inspection Report (EIR) today for the inspection carried out by the US Food and Drug Administration (USFDA) at our API - I & API - II Facility located at Panelav. The inspection was conducted from 26th May, 2025 to 31st May, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123